KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Conditional Risk and Predictive Factors Associated With Late Toxicity in Patients With Prostate Cancer Treated With External Beam Radiation Therapy Alone in the Randomized Trial RTOG 0126. PMID 38825251 · Int J Radiat Oncol Biol Phys · 2024-Nov-15 The study is a randomized, human, oncology trial (RTOG 0126) analyzing late toxicity after radiation therapy. However, it lacks a drug-containing intervention (only radiation therapy is compared) and does not report a time-to-event efficacy endpoint such as OS, PFS, DFS, etc. The primary outcomes are toxicity rates, not survival or progression. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
SMILE-stereotactic multiple fraction radiotherapy for non-spine bone metastases: study protocol for a multicenter, open-label phase III randomized controlled trial. PMID 39538259 · Trials · 2024-Nov-13 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial. PMID 39537648 · Nat Commun · 2024-Nov-13 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial. PMID 39537558 · RMD Open · 2024-Nov-13 The study is a randomized Phase III trial of adalimumab (a drug intervention) in human patients, but it is for rheumatoid arthritis, not a malignant neoplasm. Therefore, it fails the primary oncology criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Adjuvant steroid to percutaneous needle fasciotomy for Dupuytren's contracture. An RCT study protocol. PMID 39749555 · Dan Med J · 2024-Nov-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Thibang Diphatlha: a sequential multiple assignment randomized trial designed to increase timely adoption of cervical cancer treatment in Botswana. PMID 39533437 · Implement Sci Commun · 2024-Nov-12 The record describes a protocol for a randomized implementation trial (SMART design) focused on increasing timely treatment adoption for cervical cancer. It is an oncology, human, randomized study, but it is not a Phase III/IIIb or Phase II/III drug efficacy trial. The intervention consists of implementation strategies (outreach, coordination, navigation), not a drug. The primary endpoint is adoption (treatment initiation within 90 days), which is a process outcome, not a time-to-event efficacy endpoint like OS, PFS, DFS, etc. No Kaplan-Meier or HR results are reported. As it is a protocol without results, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Fever Prevention in Patients With Acute Vascular Brain Injury: The INTREPID Randomized Clinical Trial. PMID 39320879 · JAMA · 2024-Nov-12 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Effectiveness of mailed outreach and patient navigation to promote HCC screening process completion: a multicentre pragmatic randomised clinical trial. PMID 38839269 · Gut · 2024-Nov-11 The study is a randomized clinical trial on oncology screening, but it is ineligible because: (1) it is not a drug-intervention trial (intervention is mailed outreach and navigation), (2) it does not report a time-to-event efficacy endpoint (primary outcome is screening process completion, a process measure, not OS, PFS, DFS, etc.), and (3) the trial phase is not established as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial. PMID 39102622 · J Clin Oncol · 2024-Nov-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Ghost-ileostomy versus conventional loop ileostomy in patients undergoing low anterior resection for rectal cancer: results of a randomised controlled multicentre pilot trial (DRKS00013997). PMID 39520543 · Langenbecks Arch Surg · 2024-Nov-09 The study is a randomized, multicenter pilot trial in rectal cancer (oncology, human, randomized, original results). It is excluded because: 1) It is not a Phase III/IIIb or Phase II/III trial (it is a pilot study), 2) It does not involve a drug intervention (compares surgical techniques), and 3) It does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) or Kaplan-Meier analysis; endpoints are postoperative complications, function, and quality of life.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Growth differentiation factor 15 (GDF15) predicts relapse free and overall survival in unresected locally advanced non-small cell lung cancer treated with chemoradiotherapy. PMID 39511611 · Radiat Oncol · 2024-Nov-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Postoperative tumor bed radiation versus T-shaped field radiation in the treatment of locally advanced thoracic esophageal squamous cell carcinoma: a phase IIb multicenter randomized controlled trial. PMID 39511550 · BMC Med · 2024-Nov-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
"Getting Out of a Dark Place": a qualitative exploration of the impact, current coping, and what people with breast cancer hope to gain by participating in a fear of recurrence clinical trial. PMID 39508951 · Support Care Cancer · 2024-Nov-07 This is a qualitative substudy of an RCT exploring fear of recurrence and coping strategies. It does not report primary or key secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. No drug intervention is described; the focus is on psychological outcomes and coping mechanisms. The study is not a Phase III or definitive randomized trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Selection of Patients With Early-Stage Breast Cancer for Extended Endocrine Therapy: A Secondary Analysis of the IDEAL Randomized Clinical Trial. PMID 39602119 · JAMA Netw Open · 2024-Nov-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
More vs Less Frequent Follow-Up Testing and 10-Year Mortality in Patients With Stage II or III Colorectal Cancer: Secondary Analysis of the COLOFOL Randomized Clinical Trial. PMID 39570590 · JAMA Netw Open · 2024-Nov-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Recombinant Human Thyrotropin Plus Radioactive Iodine Among Patients With Thyroid Cancer: A Noninferiority Randomized Clinical Trial. PMID 39509132 · JAMA Netw Open · 2024-Nov-04 Oncology, human, randomized, Phase III trial with original primary results, but primary endpoint is not a time-to-event efficacy outcome (it's a binary success rate at a fixed timepoint), and the intervention is not a drug (recombinant human thyrotropin is a biologic stimulation agent compared against thyroid hormone withdrawal, not a cytotoxic drug). No Kaplan-Meier or HR reported.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
General health and social outcomes 50 years after exposure to antenatal betamethasone: follow-up of a randomised controlled trial. PMID 39497119 · BMC Med · 2024-Nov-04 The record describes a 50-year follow-up of a randomized trial of antenatal betamethasone for neonatal lung maturity, assessing long-term health and social outcomes. It is not an oncology study, does not involve a drug intervention in an oncology context, and does not report time-to-event efficacy endpoints relevant to the cohort criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of a WeChat-Based, Multidisciplinary, Full-Course Nutritional Management Program on the Nutritional Status of Patients With Ovarian Cancer Undergoing Chemotherapy: Randomized Controlled Trial. PMID 39496160 · JMIR Mhealth Uhealth · 2024-Nov-04 The study is a randomized trial in oncology with a drug intervention (chemotherapy) but is not a Phase III/IIIb or Phase II/III trial, and the primary outcome is nutritional status (PG-SGA scores), not a time-to-event efficacy endpoint like overall survival or progression-free survival.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Concordance of patient- and clinician-reported outcomes of acute radiation dermatitis in breast cancer. PMID 39495339 · Support Care Cancer · 2024-Nov-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Relacorilant plus nab-paclitaxel for the treatment of metastatic pancreatic ductal adenocarcinoma: results from the open-label RELIANT study. PMID 39191530 · Oncologist · 2024-Nov-04 The record is excluded because it is not a randomized trial; the study is explicitly described as a 'single-arm, phase III study.' While it meets other criteria (oncology, human, phase III, drug intervention, original results, and reports time-to-event data), the lack of randomization disqualifies it per the inclusion criteria requiring a randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A novel risk classification model integrating CEA, ctDNA, and pTN stage for stage 3 colon cancer: a post hoc analysis of the IDEA-France trial. PMID 39011625 · Oncologist · 2024-Nov-04 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Biomarkers of glucose-insulin homeostasis and incident type 2 diabetes and cardiovascular disease: results from the Vitamin D and Omega-3 trial. PMID 39488682 · Cardiovasc Diabetol · 2024-Nov-02 The record is from a randomized trial, but it is not an oncology trial focused on malignant neoplasm, the interventions are not drugs, and the primary endpoint is not a time-to-event efficacy outcome.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Choroidal and retinal alteration after long-term use of tadalafil: a prospective non-randomized clinical trial. PMID 39528356 · J Basic Clin Physiol Pharmacol · 2024-Nov-01 Study is a non-randomized prospective clinical trial in prostate cancer patients assessing ocular toxicity, not a randomized Phase II/III trial with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Application of dexmedetomidine combined with propofol-etomidate mixture in radical gastrectomy under general anesthesia. PMID 39496064 · Medicine (Baltimore) · 2024-Nov-01 While the record is an oncology RCT in humans with a drug intervention, it fails the core eligibility criteria: it is not a Phase III/IIIb or Phase II/III trial of an anticancer drug, and it lacks a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
National Liver Cancer Screening Trial (TRACER) study protocol. PMID 39495136 · Hepatol Commun · 2024-Nov-01 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Addition of prophylactic compression garments to standard care to prevent irreversible lower limb lymphoedema after gynaeco-oncological therapy (Gynolymph): protocol for a randomised controlled trial embedded within an observation cohort study. PMID 39486824 · BMJ Open · 2024-Nov-01 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Perioperative Metformin Treatment to Reduce Postoperative Hyperglycemia After Colon Cancer Surgery: A Randomized Clinical Trial. PMID 39437217 · Dis Colon Rectum · 2024-Nov-01 The study is a randomized trial in oncology patients with a drug intervention (metformin) and reports original results, but it does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, KM, or HR). The primary outcome is postoperative hyperglycemia, a metabolic/safety measure, not an oncology efficacy endpoint. The phase is not explicitly stated as III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mortality and Associated Risk Factors Among People Living With HIV With Kaposi Sarcoma: A5263/AMC066 and A5264/AMC067. PMID 39431505 · J Acquir Immune Defic Syndr · 2024-Nov-01 The report is a secondary analysis of mortality and risk factors from two randomized trials for AIDS-related Kaposi sarcoma. While it involves human oncology, randomization, and time-to-event endpoints, it is excluded because it does not present the results of a Phase III/IIIb or Phase II/III trial evaluating a specific drug-containing intervention against a control. The analysis focuses on prognostic factors (e.g., hypoalbuminemia, early progression) rather than being the primary efficacy report of a definitive randomized drug trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data. PMID 39327018 · J Nucl Med · 2024-Nov-01 The study is a non-randomized, expanded-access program analysis comparing its results to a prior phase 3 trial. It does not constitute a primary result report of a randomized trial itself, which is a required criterion for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201). PMID 39287426 · Clin Cancer Res · 2024-Nov-01 The record is a secondary analysis of a biomarker (clonal hematopoiesis) from a randomized trial. It is not the primary or key secondary efficacy report of the trial itself (Alliance A031201). The abstract reports 'No differences in OS/progression-free survival were detected' but this is a finding of the biomarker analysis, not the report of the primary drug comparison. The trial phase is not explicitly stated in the provided metadata, but even if it were Phase III, this specific report is a secondary biomarker analysis, not the definitive efficacy report required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol. PMID 39256932 · Hum Reprod · 2024-Nov-01 This is an original prospective add-on study to a Phase III randomized trial in Hodgkin lymphoma, reporting on fertility outcomes (semen parameters, hormones) as a secondary safety/toxicity endpoint. It does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for the parent trial. Therefore, it is excluded.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer. PMID 39240387 · Br J Radiol · 2024-Nov-01 Eligibility requires explicit confirmation of Phase III/IIIb or Phase II/III; this is not established in the provided record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma. PMID 39230571 · Clin Cancer Res · 2024-Nov-01 The record describes a randomized Phase III trial (EV-302/KEYNOTE-A39) with drug interventions and primary time-to-event endpoints (PFS and OS) reported as formal results for FDA approval, meeting all eligibility criteria.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Pinch Grafts Versus Second Intention Wound Healing for Mohs Micrographic Surgery Defects Below the Knee: A Prospective Randomized Trial. PMID 39088685 · Dermatol Surg · 2024-Nov-01 Prospective randomized trial on wound healing after Mohs surgery for skin cancer. While oncologic (human, randomized, original results), it lacks a Phase III classification, a drug intervention, and a time-to-event efficacy endpoint (OS, PFS, etc.). The primary endpoint is time to wound healing, not a standard oncology survival or progression endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stellate ganglion block for visceral pain in elderly patients undergoing video-assisted thoracoscopic lung cancer surgery: a randomized, controlled trial. PMID 38913440 · Int J Surg · 2024-Nov-01 Study is a randomized controlled trial in lung cancer patients but evaluates a pain management intervention (stellate ganglion block) with primary endpoints of opioid consumption and pain scores. It does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP) or Kaplan-Meier/HR analysis for an oncological outcome, thus not meeting the required efficacy endpoint criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Value and Safety of Adjuvant Radiation Therapy After Radical Cystectomy in Locally Advanced Urothelial Bladder Cancer: A Controlled Randomized Study. PMID 38879088 · Int J Radiat Oncol Biol Phys · 2024-Nov-01 The record describes a randomized trial of adjuvant radiation therapy after cystectomy for bladder cancer. It meets criteria for oncology, human, randomized trial with time-to-event endpoints and original results. However, the intervention is radiation therapy, not a drug-containing regimen. The phase of the trial is not explicitly stated in the provided metadata, and the deterministic review signal indicates phase evidence is unclear. Therefore, it does not meet the required criterion of a drug-containing intervention and explicit Phase III/IIIb or Phase II/III status.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Application of Recombinant Human Superoxide Dismutase in Radical Concurrent Chemoradiotherapy for Cervical Cancer to Prevent and Treat Radiation-induced Acute Rectal Injury: A Multicenter, Randomized, Open-label, Prospective Trial. PMID 38705489 · Int J Radiat Oncol Biol Phys · 2024-Nov-01 The study is a Phase 3 randomized trial in human oncology (cervical cancer) with a drug intervention (rhSOD enema) and reports original results. However, the primary and secondary endpoints (incidence and duration of radiation-induced diarrhea) are toxicity/safety outcomes, not time-to-event efficacy endpoints (e.g., OS, PFS, DFS, EFS, RFS, TTP) and do not involve Kaplan-Meier survival analysis or hazard ratios.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. PMID 39621951 · JCO Glob Oncol · 2024-Nov This is a cross-sectional database analysis comparing characteristics of leukemia trials, not a primary report of efficacy results from a specific randomized trial. It lacks the required drug intervention and time-to-event efficacy endpoint.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Health-Related Quality of Life and Experiences of Minor Children With Parental Cancer-A Family-Based Multilevel Analysis of Determinants. PMID 39562832 · Psychooncology · 2024-Nov The study is a non-randomized, mixed-methods interventional study assessing quality of life in children of cancer patients, without a drug intervention or time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Nurse-Led Screening-Triggered Early Specialized Palliative Care Program for Patients With Advanced Lung Cancer: A Multicenter Randomized Controlled Trial. PMID 39556485 · Cancer Med · 2024-Nov The study is a randomized controlled trial in advanced lung cancer reporting survival (a time-to-event endpoint). However, it is ineligible because the intervention is a nurse-led palliative care program, not a drug-containing intervention, and the trial phase is not explicitly identified as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pilot Randomized Controlled Trial of IN FOCUS: A Mind-Body Resiliency Intervention for Fear of Cancer Recurrence. PMID 39549022 · Psychooncology · 2024-Nov The study is a pilot randomized controlled trial (Phase II at most) of a mind-body resiliency intervention for fear of cancer recurrence. The primary outcomes are feasibility and acceptability. The efficacy endpoint is change in FCR score (a patient-reported outcome) measured at 2 and 5 months, which is not a time-to-event endpoint. There is no drug intervention. Therefore, it does not meet the required criteria for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial. PMID 39541562 · JCO Glob Oncol · 2024-Nov The trial meets the criteria for oncology, human, randomized, phase 3, and original result with a drug intervention. However, it lacks the required primary or secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR), which is explicitly stated in the abstract and deterministic review signals.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Concentration-QTcF analysis of quizartinib in patients with newly diagnosed FLT3-internal-tandem-duplication-positive acute myeloid leukemia. PMID 39533519 · Clin Transl Sci · 2024-Nov While the record is from an oncology Phase III randomized trial with a drug intervention, it is not an original result report for a primary/key secondary time-to-event efficacy endpoint. The study exclusively reports on cardiac safety (QTcF prolongation), which is a safety/pharmacodynamic outcome, and does not present survival or efficacy data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Use of CellCollector Assay to Detect Free Cancer Cells in the Peritoneal Cavity of Colorectal Cancer Patients: An Experimental Study. PMID 39503055 · Cancer Med · 2024-Nov 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Human papillomavirus-based cervical screening and long-term cervical cancer risk: a randomised health-care policy trial in Sweden. PMID 39486904 · Lancet Public Health · 2024-Nov 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. PMID 39481395 · Lancet Oncol · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Biomarker Study for Selecting Neoadjuvant Chemotherapy Regimens Based on Prognostic Prediction Using Gastric Cancer Biopsy Specimens from a Phase II Randomized Controlled Trial. PMID 39477312 · Anticancer Res · 2024-Nov 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical Benefits of new Systemic Therapy for Small-Cell Lung Cancer Over Two Decades: A Cross-Sectional Study. PMID 39476816 · Clin Respir J · 2024-Nov 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized no_km 0 Figure · 0 Panel · risk not_applicable
Clinical benefit evaluation of drug treatment regimens for advanced lung cancer:based on ASCO-VF and ESMO-MCBS. PMID 39476429 · Lung Cancer · 2024-Nov This is a systematic evaluation/review of 37 RCTs using ASCO-VF and ESMO-MCBS frameworks, not an original formal result report of a single randomized trial. It does not present primary time-to-event efficacy data (e.g., OS, PFS with KM/HR) for a specific study.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The effect of web based and traditional self breast examination education on nursing students' knowledge, skills and self-directed learning skills: A randomised controlled study. PMID 39467338 · Nurse Educ Pract · 2024-Nov The study is a randomized educational intervention trial in nursing students focused on self-breast examination skills and knowledge, not a Phase III/IIIb or Phase II/III randomized clinical trial of a drug-containing intervention for cancer treatment with a time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -